Igg International Inc Sample Contracts

BETWEEN
Safescience Inc • June 29th, 2001 • Biological products, (no disgnostic substances) • New York
AutoNDA by SimpleDocs
WARRANT -------
Safescience Inc • May 3rd, 2001 • Biological products, (no disgnostic substances)
BETWEEN
License Agreement • June 29th, 2001 • Safescience Inc • Biological products, (no disgnostic substances) • New York
For the Purchase of Shares of Common Stock of SafeScience, Inc. -----------------------------
Safescience Inc • May 3rd, 2001 • Biological products, (no disgnostic substances) • Massachusetts
Exhibit 4.1 -----------
Subscription Agreement • October 22nd, 2001 • Safescience Inc • Biological products, (no disgnostic substances) • Massachusetts
AND
Termination Agreement • April 11th, 2003 • Glycogenesys Inc • Biological products, (no disgnostic substances) • New York
WARRANT -------
Safescience Inc • April 7th, 2000 • Services-commercial physical & biological research
RECITALS:
Consulting Agreement • November 14th, 1996 • Igg International Inc • Services-commercial physical & biological research • Massachusetts
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • April 7th, 2000 • Safescience Inc • Services-commercial physical & biological research • Nevada
RECITALS
License Agreement • January 31st, 2001 • Safescience Inc • Services-commercial physical & biological research • Michigan
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • October 24th, 2005 • Glycogenesys Inc • Biological products, (no disgnostic substances) • Nevada

REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of October 21, 2005, by and between GLYCOGENESYS, INC., a Nevada corporation, (the "Company"), and FUSION CAPITAL FUND II, LLC (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Common Stock Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the "Purchase Agreement").

DAYMON ASSOCIATES, INC.
Partnership Agreement • April 28th, 2000 • Safescience Inc • Services-commercial physical & biological research
ARTICLE 1 DEFINITIONS
Development and Supply Agreement • April 11th, 2003 • Glycogenesys Inc • Biological products, (no disgnostic substances) • Washington
AND
Joint Development and Operating Agreement • June 29th, 2001 • Safescience Inc • Biological products, (no disgnostic substances) • New York
OFFICE LEASE
Office Lease • March 31st, 1998 • Safescience Inc • Services-commercial physical & biological research
AutoNDA by SimpleDocs
COMMON STOCK PURCHASE AGREEMENT
Common Stock Purchase Agreement • October 24th, 2005 • Glycogenesys Inc • Biological products, (no disgnostic substances) • Nevada

COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of October 21, 2005 by and between GLYCOGENESYS, INC., a Nevada corporation (the “Company”), and FUSION CAPITAL FUND II, LLC, an Illinois limited liability company (the “Buyer”). Capitalized terms used herein and not otherwise defined herein are defined in Section 10 hereof.

REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • March 8th, 2005 • Glycogenesys Inc • Biological products, (no disgnostic substances) • New York

This Registration Rights Agreement (the “Agreement”) is made and entered into as of this 4th day of March, 2005 by and among GlycoGenesys, Inc., a Nevada corporation (the “Company”), and the “Investors” named in that certain Purchase Agreement, dated March , 2005, by and among the Company and the Investors (the “Purchase Agreement”). Capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Purchase Agreement.

STRONG RIVER INVESTMENTS, INC. C/O GONZALEZ-RUIZ & ALEMAN (BVI) LIMITED WICKHAMS CAY I, VANTERPOOL PLAZA P.O. BOX 873 ROAD TOWN, TORTOLLA. B.V.I.
Securities Purchase Agreement • April 7th, 2000 • Safescience Inc • Services-commercial physical & biological research • New York
NONQUALIFIED STOCK OPTION AGREEMENT GLYCOGENESYS, INC.
Nonqualified Stock Option Agreement • March 23rd, 2005 • Glycogenesys Inc • Biological products, (no disgnostic substances) • Massachusetts

This Agreement confirms the grant of an option to you effective (the “Effective Date”) under the GlycoGenesys, Inc. 2003 Omnibus Incentive Plan (the “Plan”), upon the terms and conditions described herein. A copy of the Plan is being furnished to you concurrently with the execution of this Agreement.

INCENTIVE STOCK OPTION AGREEMENT GLYCOGENESYS, INC.
Incentive Stock Option Agreement • March 23rd, 2005 • Glycogenesys Inc • Biological products, (no disgnostic substances) • Massachusetts

This Agreement confirms the grant of an option to you effective (the “Effective Date”) under the GlycoGenesys, Inc. 2003 Omnibus Incentive Plan (the “Plan”), upon the terms and conditions described herein. A copy of the Plan is being furnished to you concurrently with the execution of this Agreement.

GLYCOGENESYS, INC. OPTION TO PURCHASE SHARES OF COMMON STOCK
Glycogenesys Inc • March 23rd, 2005 • Biological products, (no disgnostic substances)

GlycoGenesys, Inc. (the “Company”) hereby grants to (the “Optionee”) an Option to purchase, prior to a date ten years from the date hereof (the “Expiration Date”) all or any part of shares of Common Stock, $0.01 par value (the “Common Stock”), of the Company (the “Option Shares”), at a price of $ per share (the “Option Price”), subject to the terms and conditions set forth herein. This Option is issued pursuant to the SafeScience, Inc. 1998 Stock Option Plan (the “Plan”) as “Non-Qualified Stock Options” and are subject to all the terms and conditions of the Plan.

MANUFACTURING SUPPLY AGREEMENT
Manufacturing Supply Agreement • May 23rd, 2005 • Glycogenesys Inc • Biological products, (no disgnostic substances) • Massachusetts

This AGREEMENT is made and entered into this 10th day of March 2005 (the “Effective Date”) by and between Johnson Matthey Pharmaceutical Materials, Inc. d/b/a Johnson Matthey Pharma Services having a principal place of business at 25 Patton Road, Devens, MA 01432, (“JMPS”) and GlycoGenesys, Inc., having a principal place of business at 31 St. James Avenue, Boston, Massachusetts 02116 (“Client”). Both JMPS and Client are referred to herein individually as “Party” and collectively as the “Parties.”

Time is Money Join Law Insider Premium to draft better contracts faster.